1. Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones
- Author
-
Toru Uchiyama, Motohiro Kato, Akane Miura, Emi Mochizuki, Masafumi Onodera, Kohji Okamura, Masafumi Yamada, Tadashi Ariga, Toru Yasuda, Sirirat Takahashi, Nobuyuki Watanabe, Kazuhiko Nakabayashi, Makoto Otsu, Daisuke Tomizawa, and Kaori Edasawa
- Subjects
Genetic enhancement ,Biology ,QH426-470 ,Viral vector ,ADA activity ,medicine ,Genetics ,Progenitor cell ,retroviral vector ,Molecular Biology ,clonal dominance ,bone marrow microenvironment ,Severe combined immunodeficiency ,QH573-671 ,nonconditioned gene therapy ,medicine.disease ,Haematopoiesis ,Leukemia ,medicine.anatomical_structure ,ADA-SCID ,Immunology ,insertional mutagenesis ,Molecular Medicine ,Original Article ,Bone marrow ,Stem cell ,Cytology - Abstract
Two patients with adenosine deaminase (ADA)-deficient severe combined immunodeficiency (ADA-SCID) received stem cell-based gene therapy (SCGT) using GCsapM-ADA retroviral vectors without preconditioning in 2003 and 2004. The first patient (Pt1) was treated at 4.7 years old, and the second patient (Pt2), who had previously received T cell gene therapy (TCGT), was treated at 13 years old. More than 10 years after SCGT, T cells showed a higher vector copy number (VCN) than other lineages. Moreover, the VCN increased with differentiation toward memory T and B cells. The distribution of vector-marked cells reflected variable levels of ADA requirements in hematopoietic subpopulations. Although neither patient developed leukemia, clonal expansion of SCGT-derived clones was observed in both patients. The use of retroviral vectors yielded clonal dominance of vector-marked clones, irrespective of the lack of leukemic changes. Vector integration sites common to all hematopoietic lineages suggested the engraftment of gene-marked progenitors in Pt1, who showed severe osteoblast (OB) insufficiency compared to Pt2, which might cause a reduction in the stem/progenitor cells in the bone marrow (BM). The impaired BM microenvironment due to metabolic abnormalities may create space for the engraftment of vector-marked cells in ADA-SCID, despite the lack of preconditioning., Graphical abstract, The distribution of vector-marked cells reflected variable levels of ADA requirements in hematopoietic subpopulations in ADA-SCID gene therapy. The use of retroviral vectors yielded clonal dominance of vector-marked clones, irrespective of the lack of leukemic changes.
- Published
- 2021